- Home
- BLND vs ZNTL Comparison
BLND vs ZNTL Comparison
Compare BLND & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BLND | ZNTL |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 352.4M | 289.0M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BLND | ZNTL |
|---|---|---|
| Price | $1.52 | $3.78 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 5 |
| Target Price | $4.13 | ★ $6.60 |
| AVG Volume (30 Days) | ★ 2.3M | 1.0M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.33 | 18.03 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $123,585,000.00 | N/A |
| Revenue This Year | $12.62 | N/A |
| Revenue Next Year | $14.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.18 | $1.21 |
| 52 Week High | $4.49 | $6.95 |
Technical Indicators
Market Signals| Indicator | BLND | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 45.47 | 41.97 |
| Support Level | $1.38 | $3.46 |
| Resistance Level | $1.64 | $4.00 |
| Average True Range (ATR) | 0.09 | 0.19 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 75.00 | 38.17 |
Price Performance
Historical ComparisonAbout BLND Blend Labs Inc.
Blend Labs Inc is a cloud-based platform software platform that powers the digital interface between financial services firms and consumers. It supports and simplifies applications for mortgages, consumer loans, and deposit accounts. Its operating segment is Blend Platform segment which comprises a suite of products that power the entire origination process from back-end workflows to consumer experience. The key revenue for the company is generated from the Blend Platform segment. Company has it's assets in united states, India and Mexico regions.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.